Scleroderma Systemic Sclerosis Definition Systemic sclerosis scleroderma a
- Slides: 45
Scleroderma (Systemic Sclerosis)
Definition Systemic sclerosis (scleroderma) a multisystem disorder characterized by 1) functional and structural abnormalities of blood vessels 2) fibrosis of the skin and internal organs 3) immune system activation 4) autoimmunity Sclero=thickened, derma=skin
Epidemiology 1. Prevalence: 20 new cases per million per year 2. Susceptibility: host factor 1) age - peak occurrence: age 35 -65 years 2) gender - female : male = 4 : 1 3) genetic background 4) enviromental factors Occurs at a younger age and has a worse prognosis in African American women
Classification 1. Systemic sclerosis 2. – Diffuse cutaneous systemic sclerosis – – Limited cutaneous systemic sclerosis Overlap syndromes Localized scleroderma – Morphoea – Linear scleroderma • En coup de sabre
Classification of systemic sclerosis 1. Diffuse cutaneous systemic sclerosis 1) proximal skin thickening - distal and proximal extremity and often the trunk and face 2) tendency to rapid progression of skin change 3) rapid onset of disease following Raynaud’s phenomenon 4) early appearance of visceral involvement 5) poor prognosis
Classification of systemic sclerosis 2. Limited cutaneous systemic sclerosis 1) symmetric restricted fibrosis - affecting the distal extremities and face/neck 2) prolonged delay in appearance of distinctive internal manifestation 3) the pacients usually have Raynaud’s phenomenon for years 4) prominence of calcinosis and telangiectasia 5) good prognosis * CREST syndrome - calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia
Classification of systemic sclerosis 3. Overlap syndromes – Features of systemic sclerosis together with those of at least one other autoimmune rheumatic disease, e. g. SLE, RA, or polymyositis
Etiology Environmental factors Genetic predisposition 1) silica dust 2) organic solvents 3) biogenic amines 4) urea formaldehyde 5) polyvinyl chloride 6) rapeseed oil 7) bleomycin 8) L-tryptophan 9) silicone implant (? ) Defective immunoregulation 1) cell mediated immunity CD 4/CD 8 , cytokines 2) humoral immunity – hypergammaglobulinemia – autoantibody production – antinuclear antibody (+) > 95%
Pathogenesis Susceptible host Exogenous events Immune system activation Fibroblast activation Endothelial cell activation/damage End stage pathology Obliterative vasculopathy Fibrosis
Pathogenesis
Pathogenesis 1. Vasculopathy of small artery and capillary - endothelial cell injury - adhesion and activation of platelet - PG F, thromboxane A 2 release - vasoconstriction & growth of endothelial cell and fibroblast - narrowing or obliteration, increased permeability 2. Fibrosis - aberrant regulation of fibroblast cell growth - increased production of extracellular matrix (collagen, fibronectin, and glycosaminoglycan) - thickening of the skin & fibrosis of internal organs
Pathogenesis 3. Immune system activation producing autoantibodies: -anti-topoisomerase I (anti Scl 70) -anti-centromere -anti RNA polymerases -anti U 1 RNP -anti B 23
Clinical features 1. Vascular abnormalities 1) Raynaud's phenomenon - cold hands and feet or ears/ nose/ tongue -with reversible skin color change (white to blue to red) - induced by cold temperature or emotional stress - initial complaint in 3/4 of patients 2) digital ischemic injury
Raynaud’s phenomenon-pallor phase
Raynaud’s phenomenon-cyanotic phase
Clinical features 2. Skin involvement (1) 1) stage - edematous phase - indurative phase - atrophic phase 2) firm, thickened bound to underlying soft tissue 3) decrease in range of motion, loss of facial expression, inability to open mouth fully, contractures
Edematous phase
Skin Induration
Acrosclerosis
Facial changes Tight, thin lips with vertical perioral furrows
Salt and pepper pigmentation
Clinical features 2. Skin involvement (2) ulceration, loss of soft tissue of finger tip, pigmentation, calcific deposit, capillary change 3. Musculoskeletal system • Polyarthritis and flexion contracture • Muscle weakness and atrophy (primary /secondary)
Terminal digit resorption
Acrolysis
Digital pitting scars
CREST syndrome: C is for calcinosis
CREST : R is for Raynaud
CREST : E is for esophageal dysmotility. . . actually, you have to imagine this one CREST : S is for Sclerodactyly
CREST: T is for telangiectasia
RODNAN score
Clinical features 4. intestinal involvement 1) esophagus: hypomotility and retrosternal pain, reflux esophagitis, stricture 2) stomach: delayed emptying 3) small intestine: pseudo-obstruction, paralytic ileus, malabsorption, weight loss, cachexia 4) large intestine: chronic constipation and fecal impaction diverticula
Abnormal motility Diverticula
Clinical features 4. exocrine glands –Xerostomia –xerophthalmia 5. lungs 1) 2/3 of patients affected - leading cause of mortality and morbidity in later stage of systemic sclerosis 2) pathology - interstitial fibrosis - intimal thickening of pulmonary arterioles (pulmonary hypertension)
Pulmonary fibrosis
Clinical features 6. heart (10%): pericarditis, heart failure, arrhythmia, myocardial fibrosis 7. kidney-scleroderm renal crisis Features: HTN, microangiopathic hemolytic anemia and oliguric renal failure. Risk Factors: • Diffuse disease within the first five years • Anti-RNA polymerase III antibody • Pericardial effusion • > 15 mg prednisone daily or • Cyclosporin therapy
Laboratory findings 1. ANA, RF 2. anti-Scl-70 (DNA topoisomerase I) antibody 1) 20 -30% in diffuse scleroderma 2) 10 -15% in limited scleroderma 3. anticentromere antibody 1) 50 -90% in limited scleroderma 2) 5% in diffuse scleroderma 4. Anti RNA polymerase III Ab: 10 - 25% in Diffuse SSc, Renal Disease.
Subsets of systemic sclerosis
Diagnosis- ACR criteries 1. major criteria: proximal scleroderma 2. minor criteria: 1) sclerodactyly 2) digital pitting scar or loss of substance from the finger pads 3) bibasilar pulmonary fibrosis *the major or 2 or more minor criteria for diagnosis
Scoring Systems for Severity (? !? ) • Disease burden: The Systemic Sclerosis Severity Scale Includes nine organ systems. • Functional Assessment: Scleroderma Health Assessment Questionnaire Disability Index (SHAQ) and Scleroderma Functional Score. • Quality of Life: Short Form Health Survey (SF-36) for psychological and mental functioning
Differential dignosis • Raynaud phenomenon: primary Raynaud’s syndrome, SLE, systemic vasculitis, medicationinduced. • Skin thickening: scleredema, scleromyxedema, POEMS syndrome, diabetic cheiroarthropathy, morphea • Overlapping clinical features: SLE, Sjogren syndrome, RA, inflammatory myopathies.
Treatment A wide spectrum of clinical manifestations and severity - spontaneous improvement occurs frequently • Disease modifying interventions (? ) - methotrexate - immunosuppressive agent: cyclosporin, cyclophosphamide, mycophenolate mophetil - recombinant human relaxin • Symptomatic (organ-specific) treatment
Treatment Raynaud’s phenomenon and ischemia 1) avoid cold exposure layers of warm, loose-fitting clothing 2) quit smoking 3) vasodilator therapy - calcium channel blocker (nifedipine), prazosin, ACE-i 4) finger / toe necrosis - intravenous prostaglandin (PGE 1, PGI 2) - amputation
Treatment Gastrointestinal 1) reflux esophagitis and dysphagia - elevation of head of bed - small frequent meal - avoid lying down within 3 -4 hours of eating - abstaining from caffeine-containing beverages, cigarette smoking - H 2 blocker, proton-pump inhibitor 2) gastroparesis: promotility agent (metoclopramide) 3) malabsorption syndrome: broad spectrum antibiotics
Treatment Pulmonary 1) Interstitial fibrosis - corticosteroid - cyclophosphamide, azathioprine 2) pulmonary artery hypertension - calcium channel blocker - prostacyclin -sildenafil - transplantation Renal renal crisis: -early detection and ACE inhibitor 1 year survival without captopril 15% 1 year survival with captopril 76% - dialysis
Prognosis 1. quite variable and difficult to predict 2. cumulative survival diffuse limited 5 yr 70% 90% 10 yr 50% 70% 3. major cause of death 1) renal involvement 2) cardiac involvement 3) pulmonary involvement
- Crest syndrome
- Meggyógyultam a sclerosis multiplexből
- Is multiple sclerosis fatal
- Concept map multiple sclerosis
- Cell
- Multiple sclerosis concept map
- Hodgkin lymphoma nodular sclerosis
- Scleroderma esophagus
- Scleroderma
- Scleroderma occupational therapy
- Acrolysis finger
- Kathryn dao md
- Scleroderma face changes
- How much kontos per gallon
- Mycoses
- Local and systemic difference
- Factors affecting mobility and immobility
- Pulmonary circuit
- Emergence
- Svr calculation
- Chapter 15 preventive dentistry
- Upper limb artery
- Systemic acquired resistance in plants
- Systemic pathology exam questions pdf
- Systemic acquired resistance in plants
- Contraindication of extraction
- Bp = co x svr
- Human diseases a systemic approach
- Figure 11-6
- Local factors of wound healing
- Pulmonary systemic
- Overview of the major systemic arteries
- Label the major systemic arteries figure 47.17
- Examples of systemic barriers
- Case study 87 systemic lupus erythematosus
- Systemic circuit
- Overview of the major systemic arteries
- Correctly label the following major systemic arteries
- Systemic sustainability education
- Systemic social work
- Systematic errror
- Systemic examination of respiratory system
- Portacaval anastomosis
- Inferior vena cava relations
- Surface anatomy of liver
- Applied anthropology's systemic perspective recognizes that